You are here

  • Home
  • Archive
  • Volume 30, Issue Suppl 1
  • 3PC-015 In-use stability of Comirnaty and Spikevax clinical solutions: Pfizer-BioNTech and Moderna COVID-19 vaccines: a comparative study from a hospital pharmacy perspective

Alerts

Article menu

Download PDFPDF

Section 3: Production and compounding
3PC-015 In-use stability of Comirnaty and Spikevax clinical solutions: Pfizer-BioNTech and Moderna COVID-19 vaccines: a comparative study from a hospital pharmacy perspective
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address